FDA's John Harter
Pilot Drug Evaluation Staff former director, in valedictory speech before the Arthritis Drugs Advisory Committee Jan. 28, tells the group he has "been reassigned out of the commission" to a new office and that it is "clear the management would prefer that I didn't [remain involved] with rheumatology." A memo of a Jan. 7 PDES staff meeting states that Harter is being offered "a new position in the Office of Research Resources with collateral responsibilities in [FDA's] Staff College" ("The Pink Sheet" Jan. 24, T&G-2). Responding to the announcement, committee Chair George Ehrlich, MD, University of Pennsylvania, expressed his "personal regrets" over Harter's reassignment, saying he hopes "it will be reversed." Harter sees the brighter side: "I'm not sure that's the way to look at it, George. Whenever there's a change it's an opportunity to improve the process somehow." Harter spent the majority of time discussing his brainchild, the "NDA Day"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth